Table I.
Diagnostic biomarkers associated with primary central nervous system lymphoma.
| A, In HIV-positive patients
| ||
|---|---|---|
| First author, year | Biomarkers | (Refs.) |
| Antinori, 1999 | EBV DNA in the CSF | (34) |
|
| ||
| B, In HIV-negative patients
| ||
| First author, year | Biomarkers | (Refs.) |
|
| ||
| Sasagawa, 2015 | IL-10 | (35) |
| Song, 2016 | IL-6 | (36) |
| Rubenstein, 2013 | CXCL13 | (37) |
| Viaccoz, 2015 | Neopterin | (38) |
| Caudie, 2005 | β2-MG | (39) |
| Strehlow, 2016 | Osteopontin | (40) |
| Kersten, 1996 | sCD27 | (41) |
| Baraniskin, 2011 | Specific microRNAs | (42) |
| Rimelen, 2019 | Cell-free DNA | (45) |
| Thaler, 2017 | sTACI and sBCMA in the CSF | (46) |
| Mulazzani, 2019 | APRIL alone or in combination with BAFF in the CSF | (3) |
| Ho, 2019 | Next-generation sequencing of ctDNA from CSF | (47) |
| Deguchi, 2019 | SWI | (48) |
EBV, Epstein-Barr virus; CSF, cerebrospinal fluid; IL, interleukin; CXCL, CXC chemokine Ligand; β2-MG, β2-microglobulin; sTACI, soluble transmembrane activator and CAML interactor; sBCMA, soluble B-cell maturation antigen; APRIL, a proliferation-inducing ligand; BAFF, B-cell activating factor; ctDNA, circulating tumor DNA; SWI, susceptibility-weighted imaging.